The "Science" single domain antibody TB202-3 has shown effective binding to a variety of SARS-CoV-2 strains in preclinical studies, including α, β and γ strains

Twist Bioscience Corporation reported that the candidate antibody TB202-3 (CoVIC-094) it discovered showed that it can effectively bind to a variety of SARS-CoV-2 mutant strains, including pseudoviruses containing E484K, N501Y, D614G, Y453F and The K417N mutant strain indicates that this therapeutic antibody may be effective against a variety of COVID-19 strains

The Coronavirus Immunotherapy Alliance (CoVIC) conducted a blind analysis and confirmed that TB202-3 completely blocked the binding of the SARS-CoV-2 spike protein to human ACE2

CoVIC uses high-throughput surface plasmon resonance analysis and cryo-electron microscopy to classify antibodies that react in the SARS-CoV-2 receptor binding domain (RBD) into 7 different "communities" (RBD-1 to RBD- 7)

COVID-19 continues to evolve and will cause more mutations and virus strains

SARS-CoV-2 is an RNA virus

Dr.

Dr.

Previous studies have shown that in the preclinical hamster challenge model, at the minimum dose of 1 mg/kg, the VHH single domain "nanobody" TB202-3 has a protective effect on weight loss, which is a key indicator of disease severity

About 75% of the antibodies in the blood are IgGs

On the other hand, VHH single domain recognition target only requires one domain on the heavy chain antibody

Original search: Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study